In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib.

ABSTRACT: Peptide receptor radionuclide therapy (PRRT), a form of internal targeted radiation treatment using [¹⁷⁷Lu]Lu [DOTA⁰-Tyr³]octreotate, is used to treat patients with metastasized neuroendocrine tumors (NETs). Even though PRRT is now the second line of treatment for patients with metastasized NETs, the majority of patients will not be cured by the treatment. PRRT functions by inducing DNA damage upon radioactive decay and inhibition of DNA damage repair proteins could therefore be used as a strategy to potentiate PRRT. Previous work has shown promising results on the combination of PRRT with the PARP inhibitor olaparib in cell lines and mice and we have been taken the next step for further in vivo validation using two different xenografted mouse models. We ob

SUBMITTER: Feijtel D 

PROVIDER: S-EPMC9913849 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature